Ripretinib: A Breakthrough Targeted Therapy for GIST

aggiunto articolo blog Health

2026-01-09 08:45:47 -

Ripretinib (QINLOCK®) is a next-generation targeted therapy that marks a significant advancement in the treatment of gastrointestinal stromal tumors (GIST). Designed to address the challenges of tumor heterogeneity and drug resistance, ripretinib offers a vital treatment option for patients with advanced disease who have progressed after multiple lines of therapy. With its innovative...

0 Commenti 0 Condivisioni 35 Visualizzazioni